| Oct 25 |
Top 2 Health Care Stocks That May Fall Off A Cliff This Month
|
| Oct 24 |
First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma
|
| Oct 21 |
ImmunityBio to Participate in the Jefferies London Healthcare Conference
|
| Oct 7 |
ImmunityBio: Moving The Needle
|
| Sep 21 |
ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt
|
| Sep 12 |
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
|
| Sep 9 |
ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer
|
| Aug 19 |
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
|
| Aug 19 |
ImmunityBio's Anktiva: Promising, But Organizational Complexity Keeps Me Cautious
|
| Aug 12 |
ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval
|
